CLL
News
MRD: Powerful metric for CLL research
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.
News
B-cell cancers: Sparse insight into preventing infections
Doctors treating CLL and other B-cell cancers are blindsided by a lack of research into acquired hypogammaglobulinemia prophylactics.
News
CLL and surgery are more compatible than ever
As patients fare better with targeted therapy, physicians say they can tolerate more procedures.
News
CLL treatment: More infections among real-world patients
Among real-world blood cancer patients treated with three drugs, study finds higher infection rates than in clinical trials.
News
Surviving CLL: Higher risk of other cancer DXs
A 30-year Dutch population study highlights the medical challenges facing patients with CLL, who are now living longer.
News
Despite limits, COVID vaccines protect CLL patients
A small German study found that, in patients with CLL, COVID-19 shots don’t boost B cells but they do strengthen T cells.
News
Adding venetoclax improves ibrutinib outcomes in CLL
A small study yields sanguine news about a combination treatment, as hematologists await phase 3 results.
Conference Coverage
CLL phase 3 study: Zanubrutinib bests ibrutinib
The second-generation Bruton’s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study.
News
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
News
FDA approved acalabrutinib tablet for MCL, CLL, SLL
Acalabrutinib (Calquence) in tablet formulation approved by FDA.